Know Cancer

or
forgot password

Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity


N/A
N/A
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity


Inclusion Criteria:



- prostate cancer diagnosis

- undergoing radiotherapy

- agree to participate in study

Exclusion Criteria:

- not willing to participate

- not undergoing radiotherapy

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Nadeem Pervez, MBBS, FRCPC

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services

Authority:

Canada: Health Canada

Study ID:

GU-6-0076/ethics 23586

NCT ID:

NCT00523471

Start Date:

July 2007

Completion Date:

June 2010

Related Keywords:

  • Prostate Cancer
  • prostate cancer
  • gamma H2AX
  • radiosensitivity
  • Prostatic Neoplasms

Name

Location